Volume 16, Number 9—September 2010
CME ACTIVITY - Synopsis
Recurrent Granulibacter bethesdensis Infections and Chronic Granulomatous Disease
Table A1
Patient no. | Age, y/sex | Country of origin | Radiographic findings | Pathologic findings (site) | Leukocytes, × 103 cells/μL† | ESR, mm/h† | Duration of signs and symptoms, wk‡ | Treatment§ | Recurrence |
---|---|---|---|---|---|---|---|---|---|
1 | 39/M | USA | Cervical, mediastinal lymphadenopathy; splenic lesions | Necrotizing granulomatous inflammation (cervical lymph nodes) | 11.3 | 90 | 20 | Meropenem; doxycycline; TMP/SMX; ceftriaxone | Relapse |
2 | 36/M | USA | Cervical, mediastinal, abdominal lymphadenopathy | Necrotizing granulomatous inflammation (perigastric lymph node) | 10.2 | 50 | 8 | TMP-SMX; meropenem; tobramycin; ceftriaxone; doxycycline; cefpodoxime; γ-interferon; tigecycline | Relapse |
3 | 13/M | USA | Cervical, mediastinal, lymphadenopathy | Lymphohistiocytic infiltrate (transtracheal lymph node biopsy specimen) | 5.9 | 44 | 4 | Ceftriaxone; tobramycin; doxycycline; cefdinir | Reinfection |
4 | 17/M | Panama | Cervical, mediastinal lymphadenopathy | Necrotizing granulomatous inflammation (cervical lymph node) | NA | NA | 8 | Doxycycline | No |
5 | 37/M | USA | Cervical, mediastinal lymphadenopathy; liver and splenic lesions | Necrotizing granulomatous inflammation (supraclavicular lymph node) | 7.3 | 55 | 16 | Ceftriaxone; gentamicin; doxycycline; TMP/SMX; cefdinir | No |
*All patients have X-linked chronic granulomatous disease. ESR, erythrocyte sedimentation rate; TMP/SMX, trimethoprim/sulfamethoxazole; NA, not available.
†At time of patient visit or diagnosis of Granulibacter spp. infection at the National Institutes of Health, Bethesda, Maryland, USA.
‡From onset of symptoms to culture-confirmed infection; initial symptoms in those with recurrence.
§Drugs used specifically for treatment of G. bethesdensis infection alone or in combination during the patient’s illness. Drugs in boldface were those for which the largest clinical response was observed in that patient.
Page created: August 28, 2011
Page updated: August 28, 2011
Page reviewed: August 28, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.